Lowering heart inflammation to reduce atrial fibrillation risk in people with diabetes
Official title: Resolution of inflammation and atrial fibrillation
Funded at University of Minnesota · NIH-11512008 · Data updated 2026-11-12
Seeing whether blocking a pro-inflammatory enzyme or boosting the heart's natural inflammation-resolving signals can lower atrial fibrillation risk in people with diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | April 20, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $83,863 |
| NIH project number | 3R01HL165704-04S1 |
| Project ID | NIH-11512008 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with diabetes who have atrial fibrillation or are at high risk of developing atrial fibrillation would be the most relevant candidates.
✕Less likely to help
People whose atrial fibrillation is unrelated to diabetes or inflammatory pathways, or individuals without diabetes, may be less likely to benefit from these specific approaches.
What this research studies
Researchers will compare atrial heart tissue and cells from people and mice with and without diabetes to measure pro-inflammatory and pro-resolving lipid signals linked to atrial fibrillation. In lab and animal models they will test three approaches: inhibit the enzyme 12-LOX to reduce pro-inflammatory lipids, increase the receptor LGR6 to boost resolving signals, and decrease 15-PGDH to slow breakdown of resolving molecules. The team will measure effects on the NLRP3 inflammasome and IL-1β production, mechanisms known to trigger abnormal heart rhythms. Results will guide whether these molecular changes can reduce the triggers for atrial fibrillation and inform future therapies.
Why it matters
Potential benefit: Could lead to new treatments that lower inflammation-driven atrial fibrillation in people with diabetes.
How similar studies have gone: Preclinical studies show NLRP3/IL-1β can promote AF and that specialized pro-resolving mediators can calm inflammasome activity, but targeting 12-LOX, LGR6, or 15-PGDH for AF is a novel translational direction.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Dudley, Samuel C — University of Minnesota
- Study coordinator: Dudley, Samuel C
Related research
Other NIH-funded projects on the same topics.
-
Cardiomyocyte-fibroblast signaling in atrial fibrillation
A researcher at Baylor College of Medicine is studying how signals between heart muscle cells and supportive heart cells influence atrial fibrillation, with the goal of finding new ways to prevent or treat this common heart rhythm problem.
-
Anticoagulation in ICH Survivors with Atrial Fibrillation and Small Vessel Disease
This project looks at how to safely use blood-thinning medicines in people who survived a brain bleed and also have atrial fibrillation and small vessel disease.
-
Atrial fibrillation, clots, and stroke: the heart’s JNK2 as a target
This NIH grant explores how a heart protein called JNK2 may drive atrial fibrillation, blood clots, and stroke, and whether it could serve as a biomarker and new treatment approach.
-
A risk score to spot high-risk heart failure patients without atrial fibrillation who may need anticoagulation
A new tool uses patient data and heart MRI markers to identify heart failure patients without atrial fibrillation who might benefit from anticoagulation while minimizing bleeding risk.
-
DECIDE-AF: a shared decision tool in your health portal to help prevent strokes in atrial fibrillation
A patient-friendly tool in your electronic health record helps you and your doctor choose the right way to prevent strokes if you have atrial fibrillation.
-
Advancing Shared Decision Making for Stroke Prevention in Atrial Fibrillation
Aims to combine data from three big trials to understand how decision aids help people with atrial fibrillation choose anticoagulation to prevent stroke, in a patient-centered way.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.